dr. harold j. burstein on cdk4/cdk6 inhibitor abemaciclib in breast cancer
Published 7 years ago • 294 plays • Length 1:41Download video MP4
Download video MP3
Similar videos
-
4:09
harold burstein, md, phd on advances in breast cancer research from asco 2022
-
2:27
understanding abemaciclib: a new cdk4/6 inhibitor
-
4:35
hr breast cancer: differences between cdk4/6 inhibitors
-
2:03
harold j. burstein, md, phd, on breast cancer treatment | dana-farber cancer institute
-
3:09
dr mouabbi on the use of ribociclib vs abemaciclib in hr /her2– breast cancer
-
7:59
what are cdk 4/6 inhibitors for breast cancer?
-
3:49
harold burstein, md, phd on key advances from asco 2022
-
1:26
dr. burstein on adjuvant endocrine therapy for er breast cancer
-
18:12
tiến bộ trong điều trị ung thư vú di căn với thuốc ức chế cdk46
-
13:39
hormonal therapy for breast cancer: we teach you
-
7:13
the biological rationale for cdk4/6 inhibitors
-
7:09
abemaciclib for hr-positive metastatic breast cancer
-
0:59
dr. burstein on the results of the apt trial for her2 breast cancer
-
1:17
dr. burstein discusses pathological complete response
-
1:15
dr. burstein on the follow-up of apt trial for her2 breast cancer
-
1:23
dr. burstein on the treatment landscape of her2 breast cancer
-
6:00
options with cdk4/6 in hr metastatic breast cancer
-
4:45
cdk4/6 inhibitors for hr metastatic breast cancer
-
6:36
adjuvant cdk4/6 inhibition in early-stage hr-positive breast cancer | ruth o'regan
-
1:12
monarche: adjuvant abemaciclib in hr breast cancer
-
6:30
sabcs 2023: a look into new research for inflammatory breast cancer
-
7:43
breast cancer